Get the Stockscreener App
4.18
0.95%
-0.04
Pre-market:
4.16
-0.02
-0.48%
Aquestive Therapeutics Inc stock is traded at $4.18, with a volume of 982.66K.
It is down -0.95% in the last 24 hours and up +1.21% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$4.22
Open:
$4.22
24h Volume:
982.66K
Relative Volume:
0.34
Market Cap:
$519.51M
Revenue:
$44.55M
Net Income/Loss:
$-83.78M
P/E Ratio:
-5.3769
EPS:
-0.7774
Net Cash Flow:
$-52.99M
1W Performance:
+2.20%
1M Performance:
+1.21%
6M Performance:
-30.33%
1Y Performance:
+47.70%
1-Day Range:
$4.13
$4.29
1-Week Range:
$4.015
$4.29
52-Week Range:
$2.12
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.18 | 519.51M | 44.55M | -83.78M | -52.99M | -0.7774 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.28B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.33B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.76B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 40.70B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.28B | 3.18B | 1.33B | 1.04B | 27.90 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business ... - Caledonian Record
Aquestive Therapeutics to Report First Quarter 2026 - GlobeNewswire
AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026 - Barchart.com
MSN Money - MSN
AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026 - New Castle News
Bronstein, Gewirtz & Grossman LLC Urges Aquestive - GlobeNewswire
AQST DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class ActionAQST - TMX Newsfile
Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Press releases provided by CNW - Techaeris
aqst-pressreleasefinalx8.htm - SEC.gov
AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit - Tullahoma News
AQST DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class ActionAQST - ACCESS Newswire
AQST DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Aquestive Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Frau - The National Law Review
AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors ... - Caledonian Record
AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST - GlobeNewswire Inc.
AQST DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class ActionAQST - ACCESS Newswire
AQST DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class ActionAQST - ACCESS Newswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
AQST Technical Analysis | Trend, Signals & Chart Patterns | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesAQST - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
AQST DEADLINE ALERT: ROSEN, A Top Ranked Law Firm, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class ActionAQST - ACCESS Newswire
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Claims Pattern Of Harm: SueWallSt – Company AnnouncementFT.com - Financial Times
AQST Stockholders Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fra - GuruFocus
AQST Shareholders Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, - GlobeNewswire
AQST DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class ActionAQST - TMX Newsfile
AQST Price Today: Aquestive Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST - ChartMill
AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities LawsuitContact The Gross Law Firm - PR Newswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
AQST Shareholder Alert: Investors With Losses May Seek to Lead t - GuruFocus
AQST DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class ActionAQST - TMX Newsfile
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. - GlobeNewswire
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
AQST SEC FilingsAquestive Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
AQST DEADLINE: ROSEN, LEADING TRIAL COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class ActionAQST - TMX Newsfile
Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail - MSN
AQST DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Aquestive ... - Black Hills Pioneer
AQST DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class ActionAQST - ACCESS Newswire
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AQST DEADLINE: ROSEN, A TOP-RANKED LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class ActionAQST - TMX Newsfile
Aquestive Therapeutics, Inc. (NASDAQ: AQST) Investor Alert: Deadline in Lawsuit on May 4, 2026 - openPR.com
[ARS] Aquestive Therapeutics, Inc. SEC Filing - Stock Titan
Aquestive (NASDAQ: AQST) maps 2026 votes on board, pay and auditor - Stock Titan
Oppenheimer Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aquestive Therapeutics Inc Stock (AQST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barber Daniel | President and CEO |
Mar 10 '26 |
Sale |
4.17 |
180,677 |
753,965 |
1,004,753 |
| BRAENDER LORI J | Chief Legal Officer |
Mar 10 '26 |
Sale |
4.17 |
40,102 |
167,346 |
442,879 |
| Cioffi Melina | SVP, Regulatory Affairs |
Mar 10 '26 |
Sale |
4.17 |
25,311 |
105,623 |
274,867 |
| TOTH A ERNEST JR | Chief Financial Officer |
Mar 10 '26 |
Sale |
4.17 |
58,254 |
243,094 |
376,112 |
| Korczynski Sherry | Chief Commercial Officer |
Mar 10 '26 |
Sale |
4.17 |
15,741 |
65,687 |
241,117 |
| Jung Cassie | Chief Operating Officer |
Mar 10 '26 |
Sale |
4.17 |
45,791 |
191,086 |
274,980 |
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):